R1 RCM Inc. (NASDAQ:RCM) Receives Average Recommendation of “Moderate Buy” from Brokerages

R1 RCM Inc. (NASDAQ:RCM – Get Rating) has been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $16.85.

Several research analysts have commented on RCM shares. TheStreet downgraded R1 RCM from a “c-” rating to a “d+” rating in a research note on Monday, November 21st. Guggenheim raised R1 RCM from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Wednesday, December 7th. Cowen lowered their price target on R1 RCM from $34.00 to $25.00 in a research report on Monday, November 14th. SVB Leerink decreased their target price on R1 RCM from $35.00 to $16.00 and set an “outperform” rating for the company in a research report on Wednesday, November 9th. Finally, KeyCorp increased their price target on R1 RCM from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, February 2nd.

Insider Activity at R1 RCM

In other news, CEO Lee Rivas acquired 71,767 shares of the stock in a transaction that occurred on Tuesday, February 21st. The shares were bought at an average cost of $13.93 per share, for a total transaction of $999,714.31. Following the acquisition, the chief executive officer now owns 71,767 shares in the company, valued at approximately $999,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 63.50% of the stock is owned by company insiders.

Institutional Trading of R1 RCM

Several hedge funds have recently modified their holdings of RCM. Macquarie Group Ltd. grew its holdings in shares of R1 RCM by 11.0% during the second quarter. Macquarie Group Ltd. now owns 4,159 shares of the healthcare provider’s stock worth $88,000 after purchasing an additional 411 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in R1 RCM by 12.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,608 shares of the healthcare provider’s stock worth $97,000 after acquiring an additional 508 shares during the period. Captrust Financial Advisors grew its stake in shares of R1 RCM by 81.7% during the 2nd quarter. Captrust Financial Advisors now owns 1,664 shares of the healthcare provider’s stock valued at $35,000 after buying an additional 748 shares during the period. Federated Hermes Inc. grew its stake in shares of R1 RCM by 3.6% during the 1st quarter. Federated Hermes Inc. now owns 25,578 shares of the healthcare provider’s stock valued at $684,000 after buying an additional 893 shares during the period. Finally, Oregon Public Employees Retirement Fund boosted its position in R1 RCM by 2.4% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 40,058 shares of the healthcare provider’s stock worth $742,000 after purchasing an additional 928 shares during the period. 97.09% of the stock is currently owned by institutional investors and hedge funds.

R1 RCM Stock Performance

RCM opened at $14.09 on Tuesday. The firm’s 50-day simple moving average is $13.27 and its 200-day simple moving average is $14.74. R1 RCM has a twelve month low of $6.71 and a twelve month high of $27.86. The firm has a market cap of $5.87 billion, a price-to-earnings ratio of -100.64, a PEG ratio of 7.60 and a beta of 0.82.

R1 RCM (NASDAQ:RCM – Get Rating) last announced its quarterly earnings results on Thursday, February 16th. The healthcare provider reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.06). R1 RCM had a negative net margin of 3.19% and a positive return on equity of 0.05%. The firm had revenue of $532.80 million during the quarter, compared to analyst estimates of $519.28 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. The business’s revenue was up 33.6% on a year-over-year basis. As a group, sell-side analysts anticipate that R1 RCM will post 0.2 EPS for the current fiscal year.

R1 RCM Company Profile

(Get Rating)

R1 RCM, Inc engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.